Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Journal Volume
124
Pages
21
Date Issued
2022-08-29
Author(s)
Waits, Alexander
Chen, Jau-Yuan
Cheng, Wei-Hong
Yeh, Jih-I
Chen, Charles
Janssen, Robert
Lien, Chia En
Lin, Tzou-Yien
Abstract
Older adults are subject to higher COVID-19 infection and mortality rates. Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated in phase 2 clinical trial for the general population, and negative correlations have been observed between immune responses and age, however, older adults were under-represented.
Subjects
Immunogenicity; Immunosenescence; MVC-COV1901 vaccine; Older adults; SARS-Cov-2
SDGs
Publisher
ELSEVIER SCI LTD
Type
journal article